Holen Sie sich die Stockscreener-App
35.61
2.21%
0.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$34.84
Offen:
$34.68
24-Stunden-Volumen:
616.64K
Relative Volume:
0.72
Marktkapitalisierung:
$3.37B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-5.5039
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
+1.42%
1M Leistung:
+1.80%
6M Leistung:
-20.42%
1J Leistung:
-16.43%
1-Tages-Spanne:
$34.34
$35.67
1-Wochen-Bereich:
$34.27
$37.28
52-Wochen-Spanne:
$29.59
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
35.61 | 3.32B | 522.75M | -558.99M | -439.53M | -6.47 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx to Participate at Bank of America's 2025 Healthcare C - GuruFocus
Ultragenyx price target lowered to $100 from $140 at Truist - Yahoo Finance
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being - simplywall.st
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Decoding Ultragenyx Pharmaceutical Inc (RARE): A Strategic SWOT Insight - GuruFocus
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference - GlobeNewswire
Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth - MSN
Ultragenyx (RARE) Sees Price Target Reduced Amid Gene Therapy Outlook | RARE Stock News - GuruFocus
Ultragenyx (RARE) Stock: Citi Recommends Buy Amidst Valuation In - GuruFocus
Ultragenyx (RARE) Stock: Citi Recommends Buy Amidst Valuation Insights | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Q1 2025 Earnings Call Transcript - MarketBeat
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highl - GuruFocus
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx: Q1 Earnings Snapshot - CTPost
Ultragenyx Reports Strong Q1 2025 Revenue Growth - TipRanks
Ultragenyx (RARE) Reports Strong Q1 2025 Revenue Growth Driven b - GuruFocus
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ultragenyx misses Q1 estimates, shares fall on weak results By Investing.com - Investing.com Canada
Ultragenyx misses Q1 estimates, shares fall on weak results - Investing.com
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ultragenyx (RARE) Reports Q1 Revenue Below Expectations | RARE S - GuruFocus
Ultragenyx Pharmaceutical Inc Reports Q1 2025 Earnings: EPS of -$1.57 Beats Estimates, Revenue of $139 Million Misses Expectations - GuruFocus
Ultragenyx Pharmaceutical Q1 Loss Narrows - Nasdaq
Ultragenyx (RARE) Reaffirms FY25 Financial Outlook with Positive Revenue Growth | RARE Stock News - GuruFocus
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update - The Manila Times
Ultragenyx May 2025 slides: pipeline advances driving path to profitability - Investing.com
Ultragenyx May 2025 slides: pipeline advances driving path to profitability By Investing.com - Investing.com South Africa
X-linked Hypophosphatemia Market 2025-2032 Business Outlook, - openPR.com
Ultragenyx Pharmaceutical's Earnings: A Preview - Nasdaq
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.61 a shareEarnings Preview - TradingView
US FDA Not Industry’s ‘Sock Puppet,’ Ultragenyx’s Emil Kakkis Says - insights.citeline.com
BlackRock, Inc. Reduces Stake in Ultragenyx Pharmaceutical Inc. - GuruFocus
Ultragenyx to Host Conference Call for First Quarter 2025 Financ - GuruFocus
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):